Middle East & Africa Branded Generics Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028

Analysis – by Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics & Anti-Inflammatory, and Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, and Drug Stores), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Antihypertensive, Lipid-Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptic, and Others), and Formulation Type (Oral, Parenteral, Topical, and Others)

No. of Pages: 174
Report Code: BMIRE00026051
Category: Life Sciences
Middle East & Africa Branded Generics Market

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Middle East & Africa Branded Generics Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Middle East & Africa Branded Generics Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Middle East & Africa Branded Generics Market Regional Analysis

6.2 Middle East & Africa Branded Generics Market Revenue 2020-2028 (US$ Billion)
6.3 Middle East & Africa Branded Generics Market Forecast Analysis

7. Middle East & Africa Branded Generics Market Analysis – by Therapeutic Application

7.1 Oncology
  • 7.1.1 Overview
  • 7.1.2 Oncology: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
7.2 Cardiovascular Diseases
  • 7.2.1 Overview
  • 7.2.2 Cardiovascular Diseases: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
7.3 Diabetes
  • 7.3.1 Overview
  • 7.3.2 Diabetes: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
7.4 Neurology
  • 7.4.1 Overview
  • 7.4.2 Neurology: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
7.5 Gastrointestinal Diseases
  • 7.5.1 Overview
  • 7.5.2 Gastrointestinal Diseases: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
7.6 Dermatology Diseases
  • 7.6.1 Overview
  • 7.6.2 Dermatology Diseases: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
7.7 Analgesics & Anti-Inflammatory
  • 7.7.1 Overview
  • 7.7.2 Analgesics & Anti-Inflammatory: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)

8. Middle East & Africa Branded Generics Market Analysis – by Distribution Channel

8.1 Hospitals
  • 8.1.1 Overview
  • 8.1.2 Hospitals: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
8.2 Retail Pharmacies
  • 8.2.1 Overview
  • 8.2.2 Retail Pharmacies: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
8.3 Online Pharmacies
  • 8.3.1 Overview
  • 8.3.2 Online Pharmacies: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
8.4 Drug Stores
  • 8.4.1 Overview
  • 8.4.2 Drug Stores: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)

9. Middle East & Africa Branded Generics Market Analysis – by Drug Class

9.1 Alkylating Agents
  • 9.1.1 Overview
  • 9.1.2 Alkylating Agents: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.2 Antimetabolites
  • 9.2.1 Overview
  • 9.2.2 Antimetabolites: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.3 Hormones
  • 9.3.1 Overview
  • 9.3.2 Hormones: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.4 Antihypertensive
  • 9.4.1 Overview
  • 9.4.2 Antihypertensive: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.5 Lipid-Lowering Drugs
  • 9.5.1 Overview
  • 9.5.2 Lipid-Lowering Drugs: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.6 Antidepressants
  • 9.6.1 Overview
  • 9.6.2 Antidepressants: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.7 Antipsychotics
  • 9.7.1 Overview
  • 9.7.2 Antipsychotics: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
9.8 Antiepileptic
  • 9.8.1 Overview
  • 9.8.2 Antiepileptic: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)

10. Middle East & Africa Branded Generics Market Analysis – by Formulation Type

10.1 Oral
  • 10.1.1 Overview
  • 10.1.2 Oral: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
10.2 Parenteral
  • 10.2.1 Overview
  • 10.2.2 Parenteral: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)
10.3 Topical
  • 10.3.1 Overview
  • 10.3.2 Topical: Middle East & Africa Branded Generics Market – Revenue and Forecast, 2020-2028 (US$ Billion)

11. Middle East & Africa Branded Generics Market – Middle East and Africa Analysis

11.1 Overview

11.2 Middle East and Africa
  • 11.2.1 Middle East & Africa Branded Generics Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 11.2.1.1 Middle East & Africa Branded Generics Market – Revenue and Forecast Analysis – by Country
  • 11.2.1.1 South Africa: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
    • 11.2.1.1.1 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
    • 11.2.1.1.2 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
    • 11.2.1.1.3 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
    • 11.2.1.1.4 South Africa: Middle East & Africa Branded Generics Market Breakdown, by Formulation Type
  • 11.2.1.2 Saudi Arabia: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
    • 11.2.1.2.1 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
    • 11.2.1.2.2 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
    • 11.2.1.2.3 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
    • 11.2.1.2.4 Saudi Arabia: Middle East & Africa Branded Generics Market Breakdown, by Formulation Type
  • 11.2.1.3 UAE: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
    • 11.2.1.3.1 UAE: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
    • 11.2.1.3.2 UAE: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
    • 11.2.1.3.3 UAE: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
    • 11.2.1.3.4 UAE: Middle East & Africa Branded Generics Market Breakdown, by Formulation Type
  • 11.2.1.4 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
    • 11.2.1.4.1 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Therapeutic Application
    • 11.2.1.4.2 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Distribution Channel
    • 11.2.1.4.3 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Drug Class
    • 11.2.1.4.4 Rest of Middle East and Africa: Middle East & Africa Branded Generics Market Breakdown, by Formulation Type

12. Competitive Landscape

12.1 Heat Map Analysis
12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments

14. Company Profiles

14.1 Aspen Holdings
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
14.2 AstraZeneca
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
14.3 Bausch Health (Valeant Pharmaceuticals)
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
14.4 Dr. Reddy's Laboratories Inc.
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
14.5 GlaxoSmithKline plc
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
14.6 Hetero
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
14.7 Lupin
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
14.8 Mylan N.V.
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
14.9 Par Pharmaceuticals
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
14.10 Sandoz International Gmbh
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments
14.11 Sanofi
  • 14.11.1 Key Facts
  • 14.11.2 Business Description
  • 14.11.3 Products and Services
  • 14.11.4 Financial Overview
  • 14.11.5 SWOT Analysis
  • 14.11.6 Key Developments
14.12 Teva Pharmaceutical Industries Ltd.
  • 14.12.1 Key Facts
  • 14.12.2 Business Description
  • 14.12.3 Products and Services
  • 14.12.4 Financial Overview
  • 14.12.5 SWOT Analysis
  • 14.12.6 Key Developments

15. Appendix

15.1 About Business Market Insights
15.2 List of Abbreviations

The List of Companies - Middle East & Africa Branded Generics Market

  • Aspen Holdings
  • AstraZeneca
  • Bausch Health (Valeant Pharmaceuticals)
  • Dr. Reddy's Laboratories Inc.
  • GlaxoSmithKline plc
  • Hetero
  • Lupin
  • Mylan N.V.
  • Par Pharmaceuticals
  • Sandoz International Gmbh
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)